Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review - Cost Effectiveness and Resource Allocation
Source : https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-022-00396-7
Objectives This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF). Method We searched relevant keywords in PubMed, Scopus, Web of science, and Google Scholar to find related articles.
Conclusion: Results of cost-effectiveness analyses showed that adjunct dapagliflozin plus SCT is cost-effective compared to SCT alone despite the additional costs of the drug. Finally it can be concluded that dapagliflozin is a worldwide cost-effective as an adjunct medicine in HFrEF management.
Share
• Source: Cost Effectiveness and Resource Allocation
• Conclusion: “From the present systematic review results, it can be concluded that dapagliflozin, as a cardioprotective SGLT-2i, was cost-effective in most of the studied contexts and populations, especially in diabetic patients.”
• The researchers reviewed whether the SGLT2 inhibitor dapagliflozin plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF). The researchers included 10 studies in the review.
• Incremental quality-adjusted life-years (QALYs) favored dapagliflozin plus SCT treatment regimen.
• “In all the studies, the incremental costs per QALY was below the willingness-to-pay (WTP) threshold with the exception of one study in United Kingdom which the ICER and WTP were $83,650 and $50,000. All the studies determined the National Health Care perspective. The highest and lowest ICERs were $83,650 and $1991 per QALY in United Kingdom and Thailand, respectively,” the authors wrote.
• Limitations of the current study include the highly heterogeneous nature of the data, which precluded further meta-analysis.